PL2588086T3 - Kompozycje farmaceutyczne zawierające monohydrat mleczanu 4-amino-5-fluoro-3-[6-(4-metylopiperazyn-1-ylo)-1H-benzimidazol-2-ilo]-1H-chinolin-2-onu - Google Patents

Kompozycje farmaceutyczne zawierające monohydrat mleczanu 4-amino-5-fluoro-3-[6-(4-metylopiperazyn-1-ylo)-1H-benzimidazol-2-ilo]-1H-chinolin-2-onu

Info

Publication number: PL2588086T3
Authority: PL; Poland
Prior art keywords: benzimidazol; methylpiperazin; quinolin; fluoro; amino
Prior art date: 2010-06-30

Application number

PL11734043T

Other languages

English (en)

Inventor

Jeewan Thakur

Zhihui Qiu

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-06-30

Filing date

2011-06-29

Publication date

2019-04-30

2011-06-29 Application filed by Novartis Ag filed Critical Novartis Ag

2019-04-30 Publication of PL2588086T3 publication Critical patent/PL2588086T3/pl

Links

QDPVYZNVVQQULH-UHFFFAOYSA-N 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one 2-hydroxypropanoic acid hydrate Chemical compound O.CC(O)C(O)=O.C1CN(C)CCN1C1=CC=C(N=C(N2)C=3C(NC4=CC=CC(F)=C4C=3N)=O)C2=C1 QDPVYZNVVQQULH-UHFFFAOYSA-N 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Hematology (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

PL11734043T 2010-06-30 2011-06-29 Kompozycje farmaceutyczne zawierające monohydrat mleczanu 4-amino-5-fluoro-3-[6-(4-metylopiperazyn-1-ylo)-1H-benzimidazol-2-ilo]-1H-chinolin-2-onu PL2588086T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP10168028		2010-06-30
PCT/EP2011/060949 WO2012001074A2 (en)	2010-06-30	2011-06-29	Pharmaceutical compositions comprising 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactate monohydrate.
EP11734043.0A EP2588086B1 (en)	2010-06-30	2011-06-29	Pharmaceutical compositions comprising 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactate monohydrate.

Publications (1)

Publication Number	Publication Date
PL2588086T3 true PL2588086T3 (pl)	2019-04-30

Family

ID=42751565

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL11734043T PL2588086T3 (pl)	2010-06-30	2011-06-29	Kompozycje farmaceutyczne zawierające monohydrat mleczanu 4-amino-5-fluoro-3-[6-(4-metylopiperazyn-1-ylo)-1H-benzimidazol-2-ilo]-1H-chinolin-2-onu

Country Status (37)

Country	Link
US (1)	US9545402B2 (pl)
EP (2)	EP2588086B1 (pl)
JP (1)	JP6043281B2 (pl)
KR (2)	KR20130091319A (pl)
CN (2)	CN103068373A (pl)
AR (1)	AR081776A1 (pl)
AU (1)	AU2011273519B2 (pl)
BR (1)	BR112012033479A8 (pl)
CA (1)	CA2801826C (pl)
CL (1)	CL2012003729A1 (pl)
CO (1)	CO6650354A2 (pl)
CR (1)	CR20120623A (pl)
CU (1)	CU20120177A7 (pl)
DK (1)	DK2588086T3 (pl)
DO (1)	DOP2012000324A (pl)
EA (1)	EA026244B1 (pl)
EC (1)	ECSP13012411A (pl)
ES (1)	ES2701161T3 (pl)
GE (1)	GEP20146049B (pl)
GT (1)	GT201200348A (pl)
HU (1)	HUE042355T2 (pl)
IL (1)	IL223799A (pl)
MA (1)	MA34387B1 (pl)
MX (1)	MX345404B (pl)
MY (2)	MY163369A (pl)
NI (1)	NI201200189A (pl)
NZ (1)	NZ604055A (pl)
PE (1)	PE20130481A1 (pl)
PL (1)	PL2588086T3 (pl)
PT (1)	PT2588086T (pl)
SG (1)	SG186182A1 (pl)
TN (1)	TN2012000574A1 (pl)
TR (1)	TR201818761T4 (pl)
TW (1)	TWI583384B (pl)
UA (1)	UA109659C2 (pl)
UY (1)	UY33472A (pl)
WO (1)	WO2012001074A2 (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2013063003A1 (en)	2011-10-28	2013-05-02	Novartis Ag	Method of treating gastrointestinal stromal tumors
CA2861377A1 (en)	2012-01-31	2013-08-08	Novartis Ag	Combination of a rtk inhibitor with an anti - estrogen and use thereof for the treatment of cancer
EP2872142A1 (en)	2012-07-11	2015-05-20	Novartis AG	Method of treating gastrointestinal stromal tumors
US9395468B2 (en)	2012-08-27	2016-07-19	Ocular Dynamics, Llc	Contact lens with a hydrophilic layer
WO2014058785A1 (en)	2012-10-10	2014-04-17	Novartis Ag	Combination therapy
US9492535B2 (en)	2013-03-14	2016-11-15	Aimmune Therapeutics, Inc.	Peanut formulations and uses thereof
EP3482771B1 (en)	2013-03-14	2023-01-18	Société des Produits Nestlé S.A.	Manufacture of peanut formulations for oral desensitization
EP3988992A1 (en)	2013-11-15	2022-04-27	Tangible Science, Inc.	Contact lens with a hydrophilic layer
WO2015187736A1 (en) *	2014-06-02	2015-12-10	Allergen Research Corporation	Placebo formulations and uses thereof
CA2970010A1 (en)	2014-12-09	2016-06-16	Karen Havenstrite	Medical device coating with a biocompatible layer
TWI829098B (zh)	2015-01-02	2024-01-11	美商梅拉洛伊卡公司	細菌組成物
MX2020004683A (es)	2017-11-02	2020-08-13	Aimmune Therapeutics Inc	Metodos de inmunoterapia oral.
CN113966229A (zh)	2019-05-10	2022-01-21	爱沐疗法公司	用于改善花生过敏患者的生活质量的方法
US10835531B1 (en)	2019-06-18	2020-11-17	Oncology Venture ApS	Methods for predicting drug responsiveness in cancer patients
US20230302139A1 (en) *	2020-07-31	2023-09-28	University Of Florida Research Foundation, Incorporated	Targeted rna degradation allows precision repurposing of protein-targeted small molecule medicines to rna

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5009897A (en) *	1988-06-24	1991-04-23	Abbott Laboratories	Pharmaceutical granules and tablets made therefrom
SG174632A1 (en)	2000-09-11	2011-10-28	Novartis Vaccines & Diagnostic	Quinolinone derivatives
EP1539754A4 (en)	2002-08-23	2009-02-25	Novartis Vaccines & Diagnostic	BENZIMIDAZOLE QUINOLINONES AND USES THEREOF
US20060172006A1 (en) *	2003-10-10	2006-08-03	Vincent Lenaerts	Sustained-release tramadol formulations with 24-hour clinical efficacy
GB0504203D0 (en) *	2005-03-01	2005-04-06	Novartis Ag	Organic compounds
RU2425041C2 (ru) *	2005-05-23	2011-07-27	Новартис Аг	Кристаллические и другие формы солей, образованных из молочной кислоты и 4-амино-5-фтор-3-[6-(4-метилпиперазин-1-ил)-1н-бензимидазол-2-ил]-1н-хинолин-2-она
US20070042034A1 (en) *	2005-07-22	2007-02-22	Myriad Genetics, Incorporated	High drug load formulations and dosage forms
CN101316593B (zh) *	2005-11-29	2012-05-02	诺瓦提斯公司	喹啉酮类的制剂
EP2772257A1 (en) *	2005-11-29	2014-09-03	Novartis AG	Formulations of quinolinones
TW200843766A (en)	2007-03-09	2008-11-16	Novartis Ag	Treatment of melanoma
AR069244A1 (es)	2007-11-08	2010-01-06	Ambit Biosciences Corp	Metodos para administrar n-( 5- ter- butil- isoxixasol-3-il) -n'- (4(7-(2- morfolin-4-il- etoxi) imidazo (2,1-b) (1,3) benzotiazol -2-il) fenil) urea para tratar una enfermedad proliferante y composicion farmaceutica
AR070924A1 (es)	2008-03-19	2010-05-12	Novartis Ag	Formas cristalinas y dos formas solvatadas de sales del acido lactico de 4- amino -5- fluoro-3-(5-(4-metilpiperazin-1-il ) -1h- bencimidazol-2-il) quinolin -2-(1h) - ona
EP2108365A1 (en) *	2008-04-09	2009-10-14	LEK Pharmaceuticals d.d.	Single dosage pharmaceutical formulation comprising eprosartan mesylate
SG184311A1 (en)	2010-04-16	2012-11-29	Novartis Ag	Combination of organic compounds

2011
- 2011-06-28 UY UY0001033472A patent/UY33472A/es not_active Application Discontinuation
- 2011-06-28 AR ARP110102271A patent/AR081776A1/es unknown
- 2011-06-29 KR KR1020137002390A patent/KR20130091319A/ko not_active Application Discontinuation
- 2011-06-29 EP EP11734043.0A patent/EP2588086B1/en active Active
- 2011-06-29 CA CA2801826A patent/CA2801826C/en active Active
- 2011-06-29 EA EA201291410A patent/EA026244B1/ru not_active IP Right Cessation
- 2011-06-29 PL PL11734043T patent/PL2588086T3/pl unknown
- 2011-06-29 UA UAA201213966A patent/UA109659C2/uk unknown
- 2011-06-29 TR TR2018/18761T patent/TR201818761T4/tr unknown
- 2011-06-29 CN CN2011800320095A patent/CN103068373A/zh active Pending
- 2011-06-29 TW TW100122927A patent/TWI583384B/zh not_active IP Right Cessation
- 2011-06-29 NZ NZ604055A patent/NZ604055A/en not_active IP Right Cessation
- 2011-06-29 MA MA35575A patent/MA34387B1/fr unknown
- 2011-06-29 CN CN201710208616.1A patent/CN106943355B/zh active Active
- 2011-06-29 ES ES11734043T patent/ES2701161T3/es active Active
- 2011-06-29 EP EP18193864.8A patent/EP3446686A1/en active Pending
- 2011-06-29 MY MYPI2012005339A patent/MY163369A/en unknown
- 2011-06-29 PT PT11734043T patent/PT2588086T/pt unknown
- 2011-06-29 WO PCT/EP2011/060949 patent/WO2012001074A2/en active Application Filing
- 2011-06-29 JP JP2013517282A patent/JP6043281B2/ja active Active
- 2011-06-29 KR KR1020177035178A patent/KR101840182B1/ko active IP Right Grant
- 2011-06-29 DK DK11734043.0T patent/DK2588086T3/en active
- 2011-06-29 GE GEAP201112986A patent/GEP20146049B/en unknown
- 2011-06-29 BR BR112012033479A patent/BR112012033479A8/pt not_active Application Discontinuation
- 2011-06-29 SG SG2012089413A patent/SG186182A1/en unknown
- 2011-06-29 HU HUE11734043A patent/HUE042355T2/hu unknown
- 2011-06-29 MX MX2012015091A patent/MX345404B/es active IP Right Grant
- 2011-06-29 AU AU2011273519A patent/AU2011273519B2/en active Active
- 2011-06-29 US US13/703,120 patent/US9545402B2/en active Active
- 2011-06-29 PE PE2012002517A patent/PE20130481A1/es not_active Application Discontinuation
- 2011-11-29 MY MYPI2016002052A patent/MY177741A/en unknown
2012
- 2012-12-05 TN TNP2012000574A patent/TN2012000574A1/en unknown
- 2012-12-11 CR CR20120623A patent/CR20120623A/es unknown
- 2012-12-20 NI NI201200189A patent/NI201200189A/es unknown
- 2012-12-20 IL IL223799A patent/IL223799A/en active IP Right Grant
- 2012-12-21 GT GT201200348A patent/GT201200348A/es unknown
- 2012-12-21 DO DO2012000324A patent/DOP2012000324A/es unknown
- 2012-12-24 CU CU2012000177A patent/CU20120177A7/es unknown
- 2012-12-27 CO CO12234898A patent/CO6650354A2/es not_active Application Discontinuation
- 2012-12-28 CL CL2012003729A patent/CL2012003729A1/es unknown
2013
- 2013-01-30 EC ECSP13012411 patent/ECSP13012411A/es unknown

Also Published As

Publication number	Publication date
BR112012033479A8 (pt)	2017-10-31
CU20120177A7 (es)	2013-04-19
EP2588086B1 (en)	2018-09-12
GEP20146049B (en)	2014-02-25
EP3446686A1 (en)	2019-02-27
CR20120623A (es)	2013-02-11
WO2012001074A2 (en)	2012-01-05
TR201818761T4 (tr)	2019-01-21
TW201206903A (en)	2012-02-16
CA2801826A1 (en)	2012-01-05
DOP2012000324A (es)	2013-02-28
DK2588086T3 (en)	2019-01-07
UA109659C2 (xx)	2015-09-25
UY33472A (es)	2012-01-31
CL2012003729A1 (es)	2013-04-12
IL223799A (en)	2017-04-30
HUE042355T2 (hu)	2019-06-28
KR20130091319A (ko)	2013-08-16
EA201291410A1 (ru)	2013-05-30
NZ604055A (en)	2015-02-27
BR112012033479A2 (pt)	2016-11-29
EA026244B1 (ru)	2017-03-31
CN106943355B (zh)	2020-09-01
CA2801826C (en)	2018-04-10
WO2012001074A3 (en)	2012-03-22
KR101840182B1 (ko)	2018-03-19
MY163369A (en)	2017-09-15
MY177741A (en)	2020-09-23
MA34387B1 (fr)	2013-07-03
TWI583384B (zh)	2017-05-21
ECSP13012411A (es)	2013-03-28
KR20170139170A (ko)	2017-12-18
ES2701161T3 (es)	2019-02-21
MX2012015091A (es)	2013-02-12
US9545402B2 (en)	2017-01-17
JP6043281B2 (ja)	2016-12-14
MX345404B (es)	2017-01-30
AU2011273519A1 (en)	2013-01-31
GT201200348A (es)	2014-03-14
PE20130481A1 (es)	2013-05-01
CN103068373A (zh)	2013-04-24
PT2588086T (pt)	2018-12-18
AU2011273519B2 (en)	2014-05-15
CO6650354A2 (es)	2013-04-15
AR081776A1 (es)	2012-10-17
NI201200189A (es)	2013-12-17
US20130090344A1 (en)	2013-04-11
SG186182A1 (en)	2013-01-30
CN106943355A (zh)	2017-07-14
EP2588086A2 (en)	2013-05-08
TN2012000574A1 (en)	2014-04-01
JP2013530196A (ja)	2013-07-25

Publication	Publication Date	Title
PL2588086T3 (pl)	2019-04-30	Kompozycje farmaceutyczne zawierające monohydrat mleczanu 4-amino-5-fluoro-3-[6-(4-metylopiperazyn-1-ylo)-1H-benzimidazol-2-ilo]-1H-chinolin-2-onu
HRP20190164T1 (hr)	2019-04-05	Paraziticidni oralni veterinarski sastavi koji obuhvaćaju djelatne tvari sa sustavnim djelovanjem, i načini njihove primjene
HK1202415A1 (en)	2015-10-02	Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15- hetre and methods of use thereof dgla15-ohepa/ 15-hetre
HK1210711A1 (en)	2016-05-06	Pharmaceutical composition comprising rebamipide
HRP20160928T1 (hr)	2016-10-07	Farmaceutske kompozicije koje sadrže anakinra bez citrata
IL221087A (en)	2015-07-30	Pharmacy or nutritional composition
HK1186655A1 (zh)	2014-03-21	含有或其衍生物用作活性成分的抗瘧疾藥物